Risk factors for hematological toxicity of chemotherapy for bone and soft tissue sarcoma

Author： Ouyang Zhengxiao   Peng Dan   Dhakal Dibya Purush  

Publisher： Spandidos Publications

ISSN： 1792-1074

Source： Oncology Letters, Vol.5, Iss.5, 2013-05, pp. : 1736-1740

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemotherapy of Soft Tissue Sarcoma

By Wall Najme   Wall Najme  

Acta Oncologica, Vol. 42, Iss. 1, 2003-01 ,pp. : 55-61

Informa Healthcare

Access to resources Recommend Favorite

High-risk soft tissue sarcoma: Clinical trial and hyperthermia combined chemotherapy

By Issels Rolf D.  

International Journal of Hyperthermia, Vol. 22, Iss. 3, 2006-05 ,pp. : 235-239

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant chemotherapy of soft tissue sarcoma—current status

By Judson Ian  

Sarcoma, Vol. 4, Iss. 4, 2000-12 ,pp. : 149-150

Informa Healthcare

Access to resources Recommend Favorite

A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma

By Gortzak E.   Azzarelli A.   Buesa J.   Bramwell V.H.C.   van Coevorden F.   van Geel A.N.   Ezzat  

European Journal of Cancer, Vol. 37, Iss. 9, 2001-06 ,pp. : 1096-1103

Elsevier

Access to resources Recommend Favorite

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

By van Oosterom A.T.   Mouridsen H.T.   Nielsen O.S.   Dombernowsky P.   Krzemieniecki K.   Judson I.   Svancarova L.   Spooner D.   Hermans C.   Van Glabbeke M.   Verweij J.   for the EORTC STBSG  

European Journal of Cancer, Vol. 38, Iss. 18, 2002-12 ,pp. : 2397-2406

Elsevier

Access to resources Recommend Favorite